Form 4: UNITED THERAPEUTICS CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 21, 2026.

Summary

  • Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 21, 2026; holds 333,943 after (Indirect).
  • Open-market sale: disposed of 1,520 Common Stock at $492.97 ($749,321) on September 21, 2026; holds 332,423 after (Indirect).
  • Open-market sale: disposed of 2,680 Common Stock at $493.60 ($1,322,851) on September 21, 2026; holds 329,743 after (Indirect).
  • Open-market sale: disposed of 2,170 Common Stock at $494.82 ($1,073,751) on September 21, 2026; holds 327,573 after (Indirect).
  • Open-market sale: disposed of 2,287 Common Stock at $495.71 ($1,133,694) on September 21, 2026; holds 325,286 after (Indirect).
  • Open-market sale: disposed of 843 Common Stock at $496.62 ($418,654) on September 21, 2026; holds 324,443 after (Indirect).
  • Option exercise/conversion: disposed of 9,500 Stock Option on September 21, 2026; holds 394,910 after (Indirect).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,698,271 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Martine A Rothblatt — Director, Officer (Chairperson & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-09-21Option exercise/conversionCommon Stock9,500$118$1.1M333,943
2026-09-21Open-market saleCommon Stock1,520$493$749.3K332,423
2026-09-21Open-market saleCommon Stock2,680$494$1.3M329,743
2026-09-21Open-market saleCommon Stock2,170$495$1.1M327,573
2026-09-21Open-market saleCommon Stock2,287$496$1.1M325,286
2026-09-21Open-market saleCommon Stock843$497$418.7K324,443
2026-09-21Option exercise/conversionStock Option9,500——394,910

Key Dates

DateDescription
2026-09-21Option exercise/conversion (9,500 shares)
2026-09-21Open-market sale (1,520 shares)
2026-09-21Open-market sale (2,680 shares)
2026-09-21Open-market sale (2,170 shares)
2026-09-21Open-market sale (2,287 shares)
2026-09-21Open-market sale (843 shares)
2026-09-21Option exercise/conversion (9,500 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.